# Biotech Daily Digest — 2026-01-17

**9 items from 2 sources**

## Summary by Source

- Endpoints News: 6 items
- Fierce Biotech: 3 items


## Endpoints News

- **[JPM recap; Mirador raises $250M; Genentech’s PBM shift; and more](https://endpoints.news/jpm-recap-mirador-raises-250m-genentechs-pbm-shift-and-more/)**  
  _Sat, 17 Jan 2026 11:00:32 +0000_  
  Welcome back to Endpoints Weekly! One programming note before we dive into news from #JPM26: We won’t be sending newsletters on Monday, but we’ll be back in your inbox on Tuesday.

 The Endpoints News  ...

- **[Agomab and SpyGlass file for IPOs as investor enthusiasm builds after JPM](https://endpoints.news/agomab-and-spyglass-file-for-ipos-as-investor-enthusiasm-builds-after-jpm/)**  
  _Fri, 16 Jan 2026 22:05:40 +0000_  
  SpyGlass Pharma and Agomab Therapeutics filed for initial public offerings on Friday evening.

 The drug developers hope to build on the strong start set by Aktis Oncology’s $318 million Nasdaq listing last ...

- **[AbbVie, Genmab say Epkinly didn't prolong overall survival in lymphoma study](https://endpoints.news/abbvie-genmab-say-epkinly-didnt-prolong-overall-survival-in-lymphoma-study/)**  
  _Fri, 16 Jan 2026 21:01:22 +0000_  
  AbbVie and Genmab’s cancer drug Epkinly failed to improve overall survival in a late-stage study for diffuse large B cell lymphoma.

 The Phase 3 trial enrolled patients who had received at least one prior therapy ...

- **[Makary talks FDA's plans to combat China's biotech growth](https://endpoints.news/makary-talks-fdas-plans-to-combat-chinas-biotech-growth/)**  
  _Fri, 16 Jan 2026 19:51:37 +0000_  
  As China sees increased biotech investments, licensing deals and faster early-phase clinical trial starts, FDA Commissioner Marty Makary said his agency is reworking Phase 1 trial regulations to speed that entry process and tweaking user ...

- **[ImmunityBio's cell therapy posts encouraging early data in rare blood cancer](https://endpoints.news/immunitybio-cell-therapy-posts-encouraging-early-data-in-rare-blood-cancer/)**  
  _Fri, 16 Jan 2026 16:05:02 +0000_  
  ImmunityBio’s off-the-shelf cell therapy has shown early promise in a small trial in a rare form of lymphoma.

 The ongoing Phase 1 study, named QUILT-106, has so far signed up four patients with Waldenström non ...

- **[#JPM26: Sandoz CEO on Ozempic generic launch plans for 2026](https://endpoints.news/jpm26-sandoz-ceo-on-ozempic-generic-launch-plans-for-2026/)**  
  _Fri, 16 Jan 2026 14:42:01 +0000_  
  SAN FRANCISCO — Throughout his 53 meetings at this year's JPMorgan Healthcare Conference, Richard Saynor mulled a charitable idea about the topic on everyone's minds.

 "We're going to put a cup in the middle of ...


## Fierce Biotech

- **[<a href="https://www.fiercebiotech.com/pharma/single-product-exelixis-aims-be-top-5-solid-tumor-drugmaker-us" hreflang="en">Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO</a>](https://www.fiercebiotech.com/pharma/single-product-exelixis-aims-be-top-5-solid-tumor-drugmaker-us)**  
  _Jan 16, 2026 10:16am_  
  Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the horizon and a growing pipeline, the Cabometyx maker is aiming big.

- **[<a href="https://www.fiercebiotech.com/biotech/vedanta-significantly-reduces-headcount-fund-lead-bacteria-cocktail-program" hreflang="en">Vedanta ‘significantly’ reduces headcount to fund lead bacteria cocktail program</a>](https://www.fiercebiotech.com/biotech/vedanta-significantly-reduces-headcount-fund-lead-bacteria-cocktail-program)**  
  _Jan 16, 2026 10:44am_  
  Vedanta Biosciences has “significantly reduced” its headcount to channel its remaining resources to its lead live bacteria cocktail program.

- **[<a href="https://www.fiercebiotech.com/biotech/immunitybio-touts-15-month-complete-response-shelf-car-nk-trial" hreflang="en">ImmunityBio touts 15-month complete response in off-the-shelf CAR-NK trial</a>](https://www.fiercebiotech.com/biotech/immunitybio-touts-15-month-complete-response-shelf-car-nk-trial)**  
  _Jan 16, 2026 9:19am_  
  ImmunityBio has reported ongoing complete responses of up to 15 months in two recipients of its CAR-NK cell therapy, leading the biopharma to talk up the prospects of the off-the-shelf blood cancer treatment.
